INTRODUCTION {#sec1-1}
============

The atmosphere comprises various distinct gases, the most abundant being nitrogen (\~78%), followed by oxygen (\~21%). Helium is only present in five parts per million (0.0005%) in the lower atmosphere. Nitrogen and helium have comparable viscosity, but helium has higher thermal conductivity compared to nitrogen. As a result, when a heliox gas mixture (79% helium and 21% oxygen) is produced, it has a viscosity similar to, but a density nearly six times lowers than atmospheric air. Due to these properties, heliox has potential applications in respiratory medicine.\[[@ref1][@ref2]\] Heliox gas mixtures are known to be nontoxic, noncarcinogenic, and have no lasting effects on any human organs.\[[@ref3]\]

Due to its lower density, inhalation of heliox results in significantly lower turbulence, particularly in the more distal portions of the lung. This effect translates to a greater proportion of laminar flow and lower overall airway resistance. The decreased turbulence effect results in increased flow rates by up to 50% during heliox inhalation. This decreased turbulence remained evident even when airflow was restricted, as in the case of obstructive lung disease.\[[@ref2][@ref4]\]

PHYSICAL PROPERTIES OF HELIUM TO APPLY FOR RESPIRATORY CARE {#sec1-2}
===========================================================

Heliox is a low density gas mixture of helium and oxygen commonly used in deep diving, and also for clinical purposes, particularly in the critical care setting. Heliox breathing reduces air flow resistance within the bronchial tree in patients with obstructive lung disease, and has beneficial effects in severe asthma attacks. Heliox may also reduce the work of breathing and improve pulmonary gas exchange efficiency. Despite the encouraging results, heliox use in routine practice remains controversial because of technical implications and high costs.\[[@ref5]\] Lower density of heliox compared with the air or oxygen regardless of the concentration of helium in the mixture; improves air flow through constricted ways by transforming turbulent flow into laminar flow. Benefits are seen quickly, usually within an hour of initiation of treatment.\[[@ref6]\]

Clinical applications of heliox {#sec2-1}
-------------------------------

What follows are some clinical applications of heliox in respiratory medicine \[[Table 1](#T1){ref-type="table"}\].

###### 

Clinical applications of Heliox-driven respiratory support
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Heliox in airway obstruction {#sec2-2}
----------------------------

The potential benefits of replacing nitrogen in the inspired air with helium were initially recognized in the 1930s when Barach administered helium to asthmatic patients and patients with laryngeal obstruction for relief of dyspnea.\[[@ref7]\]

### Conscious sedation, awake intubation {#sec3-1}

In 1997, Milner and colleagues reported the use of heliox with a laryngeal mask airway (LMA) to allow for tracheostomy under conscious sedation in an extremely anxious patient. The patient was given heliox (80:20 ratio) by means of a non-rebreathing face mask and reported subjective improvement in dyspnea. Anesthesia was induced with midazolam and small doses of propofol while maintaining spontaneous respirations. A size 3 LMA was inserted and manual ventilation was started.\[[@ref8]\] Administration of heliox is usually achieved through the use of a non-rebreathing face mask with gas flows in the range of 10 L/min. We should note that while the viscosity values for helium and oxygen are similar, the density of helium is much less than that of oxygen. The low density of helium allows it to play a significant clinical role in the temporary management of some forms of airway obstruction associated with gas turbulence.\[[@ref3][@ref9]\]

### Acute vocal cord dysfunction, bilateral vocal cords paralysis {#sec3-2}

Administering a helium and oxygen mixture (heliox) reduces airway resistance and may result in rapid improvement in patients with acute vocal cord dysfunction. A trial of heliox may be appropriate because of its relatively low cost and minimal adverse effects, and this has been reported in one case series.\[[@ref10][@ref11][@ref12]\]

Heliox has also been used effectively in cases of bilateral vocal cords paralysis after radiation therapy, post-extubation stridor, and as a temporizing measure in cases of external tracheal compression due to tumor.\[[@ref13][@ref14][@ref15][@ref16][@ref17]\]

### Intrinsic endotracheal and endobronchial, mediastinal masses {#sec3-3}

Intrinsic endotracheal or endobronchial disease can pose significant airway difficulties due to airway obstruction and loss of available lung for oxygenation and ventilation. Mediastinal masses also may present extreme hazards to the airway, leading to complete airway collapse. Much of the literature on the use of heliox is limited to case descriptions.\[[@ref18][@ref19][@ref20][@ref21]\]

### Croup {#sec3-4}

Duncan treated seven children with severe croup refractory to epinephrine with heliox 70:30. They found that all patients showed a significant reduction in their croup scores and none required intubation.\[[@ref22]\] Weber, *et al*., measured croup scores in 29 children treated either with heliox via a non-rebreather mask or nebulized racemic adrenaline, and found similar improvements with both.\[[@ref23]\]

### Tracheobronchitis, subglottic stenosis {#sec3-5}

Connolly and McGuirt, detailed 14 pediatric patients (five with viral tracheobronchitis, five with inflammatory exacerbations of subglottic stenosis, and four with acute iatrogenic subglottic injury) in whom heliox was used, it would avoid intubation in 10.\[[@ref24]\]

### Exacerbations of chronic obstructive pulmonary disease {#sec3-6}

The lower density and the higher viscosity of helium, compared with nitrogen, increase the probability that flow in a rigid tube will be laminar instead of turbulent at any given flow rate. As the pressure differential that must be generated by the patient or ventilator to produce laminar flow is substantially less than that associated with turbulent flow, a helium oxygen mixture (heliox) might be expected to reduce the work of breathing in patients with air flow obstruction.\[[@ref25]\] The administration of heliox has been shown in numerous case reports and case series to reduce the work of breathing in patients with obstruction in the extrathoracic and central intrathoracic airways.\[[@ref6]\] In patients with small airway disease, including asthma or COPD, heliox is predicted to be much less effective because the cross-sectional area of the smaller airways is quite large.\[[@ref26]\] Several groups of investigators have reported that the administration of heliox to patients with moderate or severe COPD is associated with improved exercise performance. These improvements are primarily attributable to reductions in end-expiratory lung volume or dynamic hyperinflation, which contributes to the increased work of breathing in COPD patients. Furthermore, the resulting reduced intrathoracic pressure improves hemodynamic and peripheral oxygen delivery.\[[@ref25][@ref26][@ref27][@ref28][@ref29]\]

In 10 patients with pulmonary arterial catheters, heliox decreased mean pulmonary arterial pressure, right atrial pressure, and pulmonary arterial occlusion pressure and increased cardiac index. Heliox may be a useful adjunct therapy in patients with severe COPD and acute respiratory failure with persistent intrinsic positive end-expiratory pressure (PEEP)-induced hemodynamic changes despite ventilator management.\[[@ref28]\]

### Asthma {#sec3-7}

There have been four previous, randomized, placebo-controlled studies examining

heliox for the treatment of acute asthma in children. There will still be a role for a trial of heliox in selected children with refractory status asthmaticus.\[[@ref30]\]

In the first two studies by Carter *et al*., and Kudukis *et al*., 15 min of heliox therapy was provided to small groups of children.\[[@ref31][@ref32]\] In Kudukis *et al*., findings; there was improvement in clinical asthma score and pulsus paradoxus, whereas Carter *et al*., found no improvement in pulmonary function testing or clinical asthma score.

The next two randomized placebo-controlled studies were conducted in children with acute asthma in the emergency department setting: The study by Kim *et al*., with the longer duration of heliox therapy showed improvement in clinical asthma score, whereas the study by Rivera *et al*., did not.\[[@ref33][@ref34]\]

### Pneumonia and other conditions involving lower airway obstruction {#sec3-8}

Lower respiratory tract disease caused by respiratory syncytial virus (RSV) is characterized by narrowing of the airways resulting in increased airway resistance, air-trapping, and respiratory acidosis. These problems might be overcome using helium-oxygen gas mixture. In a study of electrical impedance tomography (EIT) measurements in nine subjects showed, mechanical ventilation (MV) with heliox significantly decreased respiratory system resistance. This was not accompanied by an improved CO~2~ elimination, decreased peak expiratory flow rate or decreased end expiratory lung volume. Importantly, oxygenation remained unaltered throughout the experimental protocol.\[[@ref35]\] Heliox has been used in a number of other clinical situations in which lower airway obstruction plays a significant role, particularly in children with bronchiolitis and cystic fibrosis.\[[@ref13]\] Again, the common theme is that heliox is a temporizing measure, but is not a treatment in itself.\[[@ref13]\] Similar low-level evidence suggests that heliox is effective in reducing airway pressure and improving ventilation in various forms of lower airway obstruction. These therapies generally are supportive and may facilitate patient management.\[[@ref36]\]

Other research on the use of heliox {#sec2-3}
-----------------------------------

### Nebulized drug delivery {#sec3-9}

Helium-driven albuterol would be expected to increase nebulized drug delivery, and improve gas exchange to the distal airways. Bigham *et al*., investigated the effect of heliox-powered albuterol therapy on hospital length of stay and clinical status in children with moderate to severe status asthmaticus. According to that study, heliox-powered nebulized albuterol therapy for children admitted to the hospital with moderate to severe status asthmaticus does not shorten hospital length of stay or hasten rates of clinical improvement when compared with air/oxygen-powered nebulized albuterol.\[[@ref37]\] A study performed to compare the bronchodilator effects of albuterol and ipratropium bromide through nebulization is driven by heliox with that if driven by compressed room air (AIR) during the treatment of acute exacerbation of COPD. The change in percentage of predicted forced expiratory flow after 25-75% of vital capacity that had been expelled (FEF25-75), and forced expiratory volume in 1 s (FEV1) were measured. According to this study, use of heliox as a driving gas for the updraft nebulization of bronchodilators during the first 2 h of treatment of an acute COPD exacerbation failed to improve FEV1 faster than the use of AIR. The faster improvement in FEF25-75 during the first 2 h of treatment was small and of uncertain clinical significance.\[[@ref38]\]

### Exercise tolerance {#sec3-10}

The maximum flow in the airways is determined not only by their size and compliance at the choke point, but also by physical properties of the inhaled gases. During heliox breathing, since the density of it is approximately one-third of air, flow is expected to increase as a result of decreased turbulence within the large airways. Heliox breathing increases exercise endurance tolerance in severe COPD patients.\[[@ref39]\]

### Pulmonary rehabilitation {#sec3-11}

The most promising use of Heliox mixtures would be as an adjunct to pulmonary rehabilitation in patients with severe COPD, who are still disabled by dyspnea and are unable to achieve full benefits of training, despite pharmacologic treatment and ambulatory oxygen therapy. Use of Heliox with rehabilitation needs to be tested in large controlled studies with appropriate outcome measures.\[[@ref40]\]

Hunt *et al*., in a systematic review, explored whether symptom modification (perceived levels of dyspnea) and exercise performance in COPD (either intensity or duration of work) are modified by inhalation of heliox. They summarized that eight studies supported the effectiveness of heliox in improving the intensity and endurance of exercise when compared to room air for people with COPD.\[[@ref2]\] Further studies are also needed to verify the utility of heliox as an ergogenic aid to training in pulmonary rehabilitation.\[[@ref2][@ref39]\]

### Severe respiratory failure {#sec3-12}

Winters *et al*., reported five intubated patients with acute hypoxemic respiratory failure who were treated with high-frequency oscillatory ventilation (HFOV) combined with heliox. This bimodal treatment resulted in a fast reduction of PaCO~2~ in all patients.\[[@ref41]\]

HELIOX AND MODE OF MECHANICAL VENTILATION {#sec1-3}
=========================================

The bulk of evidence for heliox-assisted therapy is in the areas of controlled MV (CMV) and synchronized intermittent mandatory ventilation (SIMV) modes of ventilation. Heliox driven volume-controlled ventilation is currently not recommended in patients needing tidal volume (VT) \<40 mL (i.e. approximately \<6 kg). Heliox-driven pressure-controlled ventilation may be used in patients down to premature neonates with endotracheal tube (ETT) size 2.0 mm internal diameter and a weight of at least 500 g and above 30. It is important to maximize the helium content to gain the greatest potential benefit of heliox MV. This means that inspired fraction of oxygen (FiO~2~) should be kept to the minimum required for adequate oxygenation, in order to optimize FiHe. This necessitates greater flexibility and tolerance of oxygen saturations. The aim is to achieve FiHe ≥0.6, that is, FiO~2~≤0.4 where possible. If a patient is hypoxic, it is preferable to use volume recruitment strategies; increase PEEP, VT, or peak inspiratory pressure (PIP) in the case of pressure-controlled ventilation before increasing FiO~2~.\[[@ref42]\]

The addition of helium has a significant effect on fraction of inspired oxygen (FiO~2~) delivery, displayed inspiratory VT, and actual delivered VT during both volume- and pressure-controlled ventilation in four ventilators commonly used in pediatric critical care. These effects are both ventilator specific and ventilation mode specific, mandating vigilance during helium ventilation in clinical practice.\[[@ref43]\]

Noninvasive ventilation {#sec2-4}
-----------------------

Noninvasive high-frequency percussive ventilation (NIHFPV) differs from HFOV in several aspects. The most evident differences are the mode of delivery of NIHFPV through a facial mask, the applied frequency, and the pressure waveform. It stresses the potential benefits of heliox combined with high-frequency ventilation for improving severe respiratory failure, particularly in the setting of uncontrollable hypercapnia.\[[@ref44]\] The use of heliox in combination with noninvasive positive pressure ventilation (NIPPV) in patients presenting with exacerbations of COPD will have to be added to the growing list of promising therapies for critically ill patients that could not be treated through other methods.\[[@ref25]\] Helium is an inert gas with a very low density (0.18 g/L), which allows it to pass through narrowed passages with less turbulence than nitrogen or oxygen. Most studies agree that heliox is extremely safe; no adverse effects have been reported. However, heliox must be administered with vigilance and continuous monitoring to avoid technical complications.\[[@ref45]\] The improved flow properties and higher CO~2~ diffusion coefficient of heliox make it an interesting adjunct in the treatment of severe airway obstruction. It is imperative to keep in mind that heliox has no direct treatment effects and is only a temporizing measure until definitive therapies take effect or the disease process resolves.\[[@ref45]\]

In a study to assess whether noninvasive ventilation with heliox may decrease the incidence of extubation failure in preterm infants with respiratory distress syndrome (RDS): Infants \<29 weeks of gestation were treated immediately after extubation with heliox combined with nasal continuous airway pressure (Hx-NCPAP) or bilevel NCPAP (Hx-BiPAP) for 24 h, while infants in the control groups were treated with conventional NCPAP or BiPAP. The primary endpoint was the comparison of the extubation failure rate in the two groups, where failure was defined as the need for MV during the 24 h following extubation. According to this study, noninvasive ventilation with heliox was not effective in decreasing extubation failure in preterm infants with RDS, but did improve their respiratory function. The findings might support the planning of large randomized controlled studies to evaluate the effectiveness of heliox noninvasive ventilation for decreasing extubation failure in premature infants.\[[@ref46]\]

CONCLUSION {#sec1-4}
==========

Reliable physical and physiological theories support the assertion that helium can improve ventilator function, especially by reducing the resistance of the airways, which is considered the main physiopathology element of obstructive syndromes. However, the level of evidence does not permit a formal recommendation to be made regarding the use of He/O~2~ in the intensive care unit (ICU). Numerous questions remain unanswered concerning the use of He/O~2~, for instance, which patients may benefit from He/O~2~ use, in the setting of COPD or asthma? Is He/O~2~ useful in combination with noninvasive MV or with aerosol delivery? And, what is the best delivery system for He/O~2~?\[[@ref47]\] Evidence continues to evolve that heliox can effectively reduce airway resistance and work of breathing in patients with severe airway obstruction and can improve delivery of aerosol by reducing turbulence and aerosol particle impact en route to the lungs. As the practice of heliox administration continues to evolve, it is very important for clinicians to understand how heliox works, and how it will affect devices and patients. No heliox administration device should be used clinically without ample training and bench testing.\[[@ref48]\] To recommend, heliox use seems to require more research based on clinical practice and observation through vaster investigations.
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